Drug
MK-8457 100 mg
Total Trials
2
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Completion Rate
0%(0/2)
Active Trials
0(0%)
Terminated
2(100%)
Phase Distribution
Ph phase_2
2
100%
Phase Distribution
0
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 2Efficacy & side effects
2(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 2 finished
Non-Completion Rate
100.0%
2 ended early
Currently Active
0
trials recruiting
Total Trials
2
all time
Status Distribution
Terminated(2)
Detailed Status
Terminated2
Development Timeline
Analytics
Development Status
Total Trials
2
Active
0
Success Rate
0.0%
Most Advanced
Phase 2
Trials by Phase
Phase 22 (100.0%)
Trials by Status
terminated2100%
Recent Activity
0 active trials
Showing 2 of 2
terminatedphase_2
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Participants With Rheumatoid Arthritis (MK-8457-010)
NCT01651936
terminatedphase_2
Safety and Efficacy of MK-8457 and Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Despite MTX Therapy (P08683, MK-8457-008)
NCT01569152
Clinical Trials (2)
Showing 2 of 2 trials
NCT01651936Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Participants With Rheumatoid Arthritis (MK-8457-010)
NCT01569152Phase 2
Safety and Efficacy of MK-8457 and Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Despite MTX Therapy (P08683, MK-8457-008)
All 2 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 2